- With Bitcoin moving sideways, altcoins have exploded in the past few days.
- Injective, Avalanche, Optimism, Chainlink and many altcoins have returned double and triple-digit gains and could trigger a corrective wave soon.
- Double-digit corrections are more than likely in the second half of November, especially if BTC slides down.
With massive rallies across the board, the cryptocurrency market capitalization has increased from roughly $831 billion to nearly $1.5 trillion in the last ten months. While the overall outlook remains undoubtedly bullish, investors need to expect the possibility of a 10% to 20% correction even during bull runs.
Here are three altcoins that exhibit signs of weakness:
- Injective Protocol (INJ)
- Avalanche (AVAX)
- Optimism (OP)
- Chainlink (LINK)
- Render (RNDR)
- Fetch.aI (FET)
Bull run corrections are part of the cycle
Bitcoin (BTC) price has produced major sell signals on the weekly as well as the daily time frames. A correction seems all but inevitable, especially after the US Securities and Exchange Commission (SEC) hinted at a delay in ETF approval.
Analysts indicate that the Bitcoin spot ETF approval chances still sit at 90% and is likely to be approved by January 2024.
Between November 2023 and January 2024, these sell signals could play out and still retain the larger bull market trend. While Bitcoin price might only slide down 10% to 20%, altcoins could easily see corrections upwards of 20%.
Read more on why Bitcoin price could crash soon - Link
Yearn Finance (YFI) price experienced a 40% correction in the Asian trading session on November 18. Most altcoins will likely face a similar fate should BTC correct.
Three altcoins that could trigger double-digit corrections
Injective (INJ) price has rallied a whopping 167% between October 12 and November 11. This impressive uptrend now looks exhausted.
- The Momentum Reversal Indicator (MRI) has flashed not one but three sell signals.
- A sweep of equal highs at $18.41 could occur next week before the altcoin shows more signs of a bearish outlook.
- Nearly 4.40% of the circulating supply is set to be unlocked in January 21, 2024.
- A 17% correction to $13.15 is likely, which is the midpoint of the 167% move.
INJ/USDT 1-day chart
While the short-term outlook might seem bearish, Injective price might rally ahead of the token unlock in January 21, 2024.
Avalanche (AVAX) price has shot up 185% between October 16 and November 13.
- The rally has cleared the liquidity resting above $22.56 hurdle.
- If there is a weekly swing failure where AVAX produces a weekly candlestick close below $22.56, it could trigger a 30% correction to $15.56.
- In some cases, AVAX could retest the $14.67 support level.
AVAX/USDT 1-week chart
Optimism (OP) price has inflated by 67% between October 16 and November 13, which is not as mush as INJ or AVAX.
- The weekly Relative Strength Index (RSI) for OP has overcome the 50 mean level recently.
- The RSI flip, while bullish, could see a pullback to retest the midpoint. This pullback could cause OP to drop nearly 20% and tag the key weekly support level of $1.41.
OP/USDT 1-week chart
While the short-term correction outlook for OP is bearish, the long-term outlook, however, remains largely bullish. A recovery above the $1.91 support level could push Optimism price to kickstart a massive uptrend to $3.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.